TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

NCT07342738 | Not Yet Recruiting Early Phase 1

• 1 other identifier: BT004 TCR-T
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-arm, Multicenter, open-label clinical study aimed at evaluating the safety and efficacy of TCR-T injection in patients with advanced solid tumors induced by KRAS mutations.

Conditions

KRAS G12V; KRAS G12D; Solid Tumor

Outcome Measures

Primary Outcomes (2)

• Adverse Events (AEs)

  Incidence and severity of adverse events

  1 year

• Serious Adverse Events (SAEs)

  Incidence and severity of serious adverse events

  1 year

Secondary Outcomes (9)

• Objective Response Rate (ORR)

  1 year

• Disease Control Rate (DCR)

  1 year

• Duration of response (DOR)

  1 year

• Time to response (TTR)

  1 year

• Progression-free survival (PFS)

  1 year

Study Arms (1)

TCR-T cells

EXPERIMENTAL

TCR-T cells targeted for KRAS mutation

Biological: TCR-T cells; Drug: Fludarabine; Drug: Cyclophosphamide

Interventions

TCR-T cells BIOLOGICAL

TCR-T cell injection will be administered intravenously after lymphodepletion.

TCR-T cells

Fludarabine DRUG

Fludarabine is used for lymphodepletion.

TCR-T cells

Cyclophosphamide DRUG

Cyclophosphamide is used for lymphodepletion.

TCR-T cells

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntary signing of an informed consent form (ICF)；
• Males or females, aged 18-70 years (inclusive);
• Subjects with advanced solid tumors confirmed by histology/cytology, have failed with standard treatment, or intolerant to standard treatment, or no standard treatment exists：1）Colorectal cancer：failed or intolerant to at least two lines of standard treatment.2）Non-small cell lung cancer：Absence of the following gene mutations (Epidermal Growth Factor Receptor\[EGFR\]、Anaplastic Lymphoma Kinase\[ALK\] 、 Proto-oncogene tyrosine-protein kinase 1\[ROS1\]) and having failed or intolerant to platinum-based chemotherapy and/or immunotherapy and/or anti-angiogenic therapy.3）Other advanced solid tumors：failed with standard treatment, or intolerant to standard treatment, or no standard treatment exist.
• At least one measurable lesion (according to Response Evaluation Criteria in Solid Tumors\[RECIST\], version 1.1);
• Patients with tumor tissue or peripheral blood testing positive for KRAS-G12V or G12D mutations and expression of matching HLA-A\*11:01 or HLA-C\*01:02 subtypes;
• ECOG (Eastern Cooperative Oncology Group)≤2;
• Life expectancy ≥3 months;
• Adequate functional reserve of organs：1）Hematology (no intensive blood transfusion, platelet transfusion or cell growth factor performed within 14 days before the test)：·Absolute neutrophil count ≥1×10E9/L;·Platelet count ≥50×10E9/L, hemoglobin\>90g/L;·Absolute lymphocyte count ≥0.5×10E9/L;2）Blood chemistry：·Alanine aminotransferase (ALT) ≤3×Upper Limit of Normal (ULN);·Aspartate aminotransferase (AST) ≤3×ULN（patients with hepatic metastasis, ALT and AST ≤5×ULN）;·Serum creatinine ≤1.5×ULN or Creatinine clearance ≥50 mL/min;·Total bilirubin (TB) ≤1.5×ULN；3）Blood chemistry：·APTT≤1.5×ULN，INR≤1.5×ULN4）The subject has left ventricular ejection fraction (LVEF) ≥ 50% and no clinically significant pericardial effusion diagnosed by echocardiography;5）No clinically significant electrocardiographic abnormality;6）Basic oxygen saturation is \>92% under the indoor natural air environment.
• Women of childbearing age must be negative for blood HCG (Human Chorionic Gonadotropin) pregnancy test (by immunofluorescence method) at screening and baseline periods, and agree to use effective contraception for at least 1 year after infusion; and male subjects whose partners are women of childbearing age must agree to use effective barrier contraception methods and avoid sperm donation for at least 1 year after infusion.

You may not qualify if:

• Other malignancies (except non-melanoma skin cancer with the disease-free survival of more than 5 years and cervical carcinoma in situ, bladder cancer, or breast cancer);
• History of organ transplantation；
• A history of mental disorders, which may affect compliance with this protocol or lead to failure in signing the ICF;
• A history of autoimmune diseases (e.g., Crohn's disease, rheumatoid arthritis and systemic lupus erythematosus) requiring systemic immunosuppressive/systemic disease-modulating drugs；
• Poorly controlled hypertension with drug (systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>100 mmHg) or occurrence of grade III-IV heart failure or myocardial infarction, cardiac angioplasty or stent placement, unstable angina pectoris, or other clinically significant heart diseases within one year prior to signing the ICF; Corrected QT Interval (QTc) interval \>450 ms for males or QTc interval \>470 ms for females during screening (QTc interval calculated using the Fridericia formula)；
• Patients with intestinal obstruction or obstructive jaundice and are deemed ineligible for enrollment by the investigator；
• Symptomatic intracranial metastases, or moderate to severe ascites or pleural effusion requiring drainage to relieve symptoms；
• A history of or any central nervous system disorders, such as epileptic seizure, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving the central nervous system within the past 6 months；
• A positive result obtained in any of the following virological tests:1）Antibody to human immunodeficiency virus (HIV antibody); 2）Hepatitis C virus antibody (HCV antibody), with a positive result for hepatitis C virus ribonucleic acid (HCV RNA); 3）Positive for hepatitis B surface antigen (HBsAg); or positive for hepatitis B core antibody (HBcAb) and positive for hepatitis B virus deoxyribonucleic acid (HBV DNA) copies ≥2000 IU/mL; 4）Treponema pallidum antibody (TP antibody) and positive for unheated serum reagin test;
• Fungal, bacterial, viral or other infections or suspected fungal, bacterial, viral or other infections that cannot be controlled or require intravenous administration；
• Significant tendency for bleeding, such as active gastrointestinal bleeding, coagulation disorders；
• Deep vein thrombosis requiring treatment within the past 6 months, unless the risk of thrombosis is acceptable after treatment, as assessed by the investigator；
• Interstitial lung disease (such as interstitial pneumonia, pulmonary fibrosis), or a history of clinically significant respiratory system diseases at screening；
• Use of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 2 weeks prior to leukapheresis；
• Participation in any other clinical studies within 1 month prior to signing the master informed consent form；

Sponsors & Collaborators

• Sun Yat-sen University: lead
• Shanghai Bintie Biotechnology Co., Ltd: collaborator

Study Sites (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

Location

MeSH Terms

Interventions

fludarabine; Cyclophosphamide

Intervention Hierarchy (Ancestors)

Phosphoramide Mustards; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Hydrocarbons; Organic Chemicals; Phosphoramides; Organophosphorus Compounds

Central Study Contacts

Yu-hong Li, MD, Ph D

CONTACT

87342487; liyh@sysucc.org.cn

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: January 5, 2026
• First Posted: January 15, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): February 1, 2028
• Study Completion (Estimated): February 1, 2029
• Last Updated: January 15, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)